3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
17
Carcinoma, Renal Cell
14
Neoplasms
12
Neoplasm Metastasis
9
Neuroendocrine Tumors
7
Head and Neck Neoplasms
7
Kidney Neoplasms
6
Pancreatic Neoplasms
5
Prostatic Neoplasms
4
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Waldenstrom Macroglobulinemia
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Somatostatinoma
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Insulinoma
2
Hodgkin Disease
2
Interventions
Flow Cytometry
2
talactoferrin alfa
1
perifosine
1
cabozantinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alovudine
1
alectinib
1
Vorinostat
1
Trastuzumab
1
Tissue Array Analysis
1
Taxes
1
Sunitinib
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Polymerase Chain Reaction
1
Paclitaxel
1
Oxaliplatin
1
Oligonucleotide Array Sequence Analysis
1
Microarray Analysis
1
Mass Spectrometry
1
Magnetic Resonance Spectroscopy
1
Immunohistochemistry
1
Immunoenzyme Techniques
1
Gene Expression Profiling
1
Fluorodeoxyglucose F18
1
Fluorescent Antibody Technique
1
Everolimus
1
Electroacupuncture
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Salivary Gland Neoplasms
×
Everolimus
×
Clear all
NCT01313390
2011-12-12
DORA
University College, London
Phase 1/2
Terminated
4 enrolled